Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vir Biotechnology Inc V.VIR


Primary Symbol: VIR

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.


NDAQ:VIR - Post by User

Comment by Motherlode5155on Aug 04, 2020 7:32pm
129 Views
Post# 31364279

RE:RE:Exp grows the best weed!!

RE:RE:Exp grows the best weed!!I was very disappointed Exp could not take advantage of the initial weed stock frenzy in 2018. But, I experienced the same  during the Dot com times.  Same thing happened then.  Lots of illegitimate pump and dump stocks got filtered out during the crash, but the companies that survived did extremely well.  I knew the risks, but me and  many of my fellow investors are in it for the long term growth.  I estimate more than 60% of the shares of Exp are now held by investors like me.  That is why you don't see too many shares available for sale.  I have been taking advantage of the cheap shares available little bit at a time to lower my average price.   I must confess, I may be contributing to the lowering of the price as I have been bidding lower than the ask each time.  But, if you are desperate to sell,  I'm going to take advantage.  I can't blame the management for 100% of the price drop so far as this sector has moved en masse.  I am confident this company has something good to sell, and I am willing to bet my hard earned money on it.  
<< Previous
Bullboard Posts
Next >>